Holen Sie sich die Stockscreener-App
16.12
0.19%
0.03
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: - GuruFocus
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q4 2025 Earnings Conference - 富途牛牛
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - TradingView
Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Q4 Earnings Miss Expectations - GuruFocus
Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus
Summit Therapeutics (SMMT) Highlights Progress in Cancer Drug De - GuruFocus
Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf RegistrationHas The Bull Case Changed? - Yahoo! Finance Canada
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss - Investing.com Nigeria
Summit Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Summit Therapeutics (SMMT) Updates on HARMONi-3 Trial Progress - GuruFocus
Summit Therapeutics falls on earnings miss despite progress By Investing.com - Investing.com South Africa
Summit Therapeutics falls on earnings miss despite progress - Investing.com
Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks
Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise - marketscreener.com
Summit Therapeutics Inc. SEC 10-K Report - TradingView
Summit Therapeutics: Q4 Earnings Insights - Benzinga
Summit Therapeutics (NASDAQ: SMMT) posts 2025 loss but ends year with $713M cash - Stock Titan
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - Yahoo Finance
Summit Therapeutics (SMMT) Shows Elevated Options Activity Ahead of Earnings - GuruFocus
Highs Report: Can Summit Therapeutics Inc stock outperform in a bear marketJuly 2025 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Summit Therapeutics Set to Announce Q4 Earnings on February 23 - Intellectia AI
Summit Therapeutics (SMMT) Set to Release Q4 Earnings - GuruFocus
Preview: Summit Therapeutics's Earnings - Benzinga
Skandinaviska Enskilda Banken AB publ Has $6.99 Million Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
Precision Trading with Summit Therapeutics Inc. (SMMT) Risk Zones - Stock Traders Daily
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - BioSpace
Market Rankings: Will Summit Therapeutics Inc outperform the market in YEAR2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough - Yahoo Finance
Summit Therapeutics (SMMT) to Release Earnings on Monday - MarketBeat
Is Summit Therapeutics Inc. stock near bottom after decline2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Can Summit Therapeutics Inc. stock outperform in a bear marketWeekly Profit Summary & Weekly Setup with High ROI Potential - mfd.ru
Analysis Recap: How is STSSW managing supply chain issuesJuly 2025 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Bitget
FDA accepts Summit Therapeutics’ (SMMT) BLA for ivonescimab in NSCLC with November 14 PDUFA date following positive phase III data - MSN
Summit Therapeutics Insiders Placed Bullish Bets Worth US$275.0m - 富途牛牛
Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date - simplywall.st
Is Summit Therapeutics Inc. stock a good pick for beginnersMarket Activity Report & Risk Controlled Daily Plans - baoquankhu1.vn
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential - Sahm
First Week of February 20th Options Trading For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance
Technical Reactions to SMMT Trends in Macro Strategies - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com - Investing.com Canada
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Finviz
Merger Talk: Is Summit Therapeutics Inc impacted by rising rates2025 Buyback Activity & Fast Moving Stock Trade Plans - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Reaches New 12-Month LowShould You Sell? - MarketBeat
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN
0.20%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):